A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Tumor response as assessed by RECIST
6 weekly
No
Lawrence P Leichman, MD
Principal Investigator
Aptium Oncology Gastrointestinal Cancer Consortium
United States: Food and Drug Administration
D9010C00008
NCT00912743
May 2009
March 2012
Name | Location |
---|---|
Research Site | Anaheim, California |
Research Site | Boulder, Colorado |
Research Site | Lewes, Delaware |
Research Site | Boca Raton, Florida |
Research Site | Albany, New York |
Research Site | Asheville, North Carolina |
Research Site | Allentown, Pennsylvania |
Research Site | Chattanooga, Tennessee |
Research Site | Auburn, Washington |